6/24/2019 9:02:04 AM
PDL BioPharma Elects Natasha Hernday To Board
6/3/2019 7:35:06 AM
Astellas Pharma, Seattle Genetics Announce Enfortumab Vedotin Produced Tumor Response Rate Of 44%
4/25/2019 4:28:34 PM
Seattle Genetics Q1 Loss/share $0.08 Vs. Loss $0.73 Year Ago
3/29/2019 8:09:42 AM
Seattle Genetics Closes Enrollment In Tisotumab Vedotin Phase 2 Clinical Trial In Recurrent/Metastatic Cervical Cancer
3/28/2019 3:25:21 AM
Seattle Genetics, Astellas Announce Results From Trial Of Enfortumab Vedoti
3/27/2019 8:08:31 AM
Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At AACR Annual Meeting
3/25/2019 7:32:25 AM
William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
2/11/2019 8:05:39 AM
Seattle Genetics Achieves $30 Mln Milestone Payment For EC Approval Of ADCETRIS
2/7/2019 4:37:48 PM
Seattle Genetics Q4 Loss/share $0.75 Vs. Loss $0.41 Year Ago
1/9/2019 8:09:19 AM
Seattle Publishes North American Subgroup Data From ECHELON-1 Phase 3 Trial Of ADCETRIS In Newly Diagnosed Advanced HL
12/3/2018 9:31:26 PM
Seattle Genetics And Takeda Present Positive Data From Phase 3 ECHELON-2 Trial For ADCETRIS
12/1/2018 12:30:24 PM
Seattle Genetics Highlights Multiple Data Sets Evaluating Combination Of ADCETRIS And Opdivo At ASH Annual Meeting
11/16/2018 12:11:54 PM
Seattle Genetics Announces FDA Approval Of ADCETRIS In Combination With Chemotherapy For Adults
11/15/2018 8:04:24 AM
Seattle Genetics: FDA Grants Breakthrough Therapy Designation To ADCETRIS For Frontline Peripheral T-Cell Lymphomas